These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 3610554

  • 1. Ocular disposition of aminozolamide in the rabbit eye.
    Putnam ML, Schoenwald RD, Duffel MW, Barfknecht CF, Segarra TM, Campbell DA.
    Invest Ophthalmol Vis Sci; 1987 Aug; 28(8):1373-82. PubMed ID: 3610554
    [Abstract] [Full Text] [Related]

  • 2. Characterization of arylamine acetyltransferase in the rabbit eye.
    Campbell DA, Schoenwald RD, Duffel MW, Barfknecht CF.
    Invest Ophthalmol Vis Sci; 1991 Jul; 32(8):2190-200. PubMed ID: 2071333
    [Abstract] [Full Text] [Related]

  • 3. A comparison between the effect of topical and systemic carbonic anhydrase inhibitors on aqueous humor secretion.
    Brechue WF, Maren TH.
    Exp Eye Res; 1993 Jul; 57(1):67-78. PubMed ID: 8405174
    [Abstract] [Full Text] [Related]

  • 4. On the pharmacology of L-645,151: a topically effective ocular hypotensive carbonic anhydrase inhibitor.
    Sugrue MF, Gautheron P, Schmitt C, Viader MP, Conquet P, Smith RL, Share NN, Stone CA.
    J Pharmacol Exp Ther; 1985 Feb; 232(2):534-40. PubMed ID: 3838190
    [Abstract] [Full Text] [Related]

  • 5. Biopharmaceutical explanation for the topical activity of 6-hydroxyethoxy-2-benzothiazolesulfonamide in the rabbit eye.
    Lee DY, Schoenwald RD, Barfknecht CF.
    J Ocul Pharmacol; 1992 Feb; 8(3):247-65. PubMed ID: 1453087
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics, acid-base balance and intraocular pressure effects of ethyloxaloylazolamide--a novel topically active carbonic anhydrase inhibitor.
    Sharir M, Pierce WM, Chen D, Zimmerman TJ.
    Exp Eye Res; 1994 Jan; 58(1):107-16. PubMed ID: 8157096
    [Abstract] [Full Text] [Related]

  • 7. L-662,583 is a topically effective ocular hypotensive carbonic anhydrase inhibitor in experimental animals.
    Sugrue MF, Gautheron P, Mallorga P, Nolan TE, Graham SL, Schwam H, Shepard KL, Smith RL.
    Br J Pharmacol; 1990 Jan; 99(1):59-64. PubMed ID: 2110013
    [Abstract] [Full Text] [Related]

  • 8. Aminozolamide suspension: the role of the vehicle in a topical carbonic anhydrase inhibitor.
    Lewis RA, Schoenwald RD, Barfknecht CF.
    J Ocul Pharmacol; 1988 Jan; 4(3):215-9. PubMed ID: 3198983
    [Abstract] [Full Text] [Related]

  • 9. Site of ocular hydrolysis of a prodrug, dipivefrin, and a comparison of its ocular metabolism with that of the parent compound, epinephrine.
    Anderson JA, Davis WL, Wei CP.
    Invest Ophthalmol Vis Sci; 1980 Jul; 19(7):817-23. PubMed ID: 7390729
    [Abstract] [Full Text] [Related]

  • 10. Ocular distribution studies of the topical carbonic anhydrase inhibitors L-643,799 and L-650,719 and related alkyl prodrugs.
    Grove J, Gautheron P, Plazonnet B, Sugrue MF.
    J Ocul Pharmacol; 1988 Jul; 4(4):279-90. PubMed ID: 3246565
    [Abstract] [Full Text] [Related]

  • 11. The ocular penetration of topical forskolin and its effects on intraocular pressure, aqueous flow rate and cyclic AMP level in the rabbit eye.
    Matsumoto S, Yamashita T, Araie M, Kametani S, Hosokawa T, Takase M.
    Jpn J Ophthalmol; 1990 Jul; 34(4):428-35. PubMed ID: 1964483
    [Abstract] [Full Text] [Related]

  • 12. Determination of ethoxzolamide in the iris/ciliary body of the rabbit eye by high-performance liquid chromatography: comparison of tissue levels following intravenous and topical administrations.
    Eller MG, Schoenwald RD.
    J Pharm Sci; 1984 Sep; 73(9):1261-4. PubMed ID: 6491947
    [Abstract] [Full Text] [Related]

  • 13. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits.
    Acheampong AA, Shackleton M, Tang-Liu DD.
    Drug Metab Dispos; 1995 Jul; 23(7):708-12. PubMed ID: 7587958
    [Abstract] [Full Text] [Related]

  • 14. Modulation of ocular hydrodynamics and iris function by bremazocine, a kappa opioid receptor agonist.
    Russell KR, Wang DR, Potter DE.
    Exp Eye Res; 2000 May; 70(5):675-82. PubMed ID: 10870526
    [Abstract] [Full Text] [Related]

  • 15. Ocular penetration and hypotensive activity of the topically applied carbonic anhydrase inhibitor L-645,151.
    Bar-Ilan A, Pessah NI, Maren TH.
    J Ocul Pharmacol; 1986 May; 2(2):109-20. PubMed ID: 3503100
    [Abstract] [Full Text] [Related]

  • 16. Intraocular production and release of nerve growth factor after iridectomy.
    Lambiase A, Bonini S, Manni L, Ghinelli E, Tirassa P, Rama P, Aloe L.
    Invest Ophthalmol Vis Sci; 2002 Jul; 43(7):2334-40. PubMed ID: 12091435
    [Abstract] [Full Text] [Related]

  • 17. Relations among IOP reduction, ocular disposition and pharmacology of the carbonic anhydrase inhibitor ethoxzolamide.
    Maren TH, Brechue WF, Bar-Ilan A.
    Exp Eye Res; 1992 Jul; 55(1):73-9. PubMed ID: 1397133
    [Abstract] [Full Text] [Related]

  • 18. Ocular hypotensive action of a dopaminergic (DA2) agonist, 2,10,11-trihydroxy-N-n-propylnoraporphine.
    Ogidigben M, Chu TC, Potter DE.
    J Pharmacol Exp Ther; 1993 Nov; 267(2):822-7. PubMed ID: 7902435
    [Abstract] [Full Text] [Related]

  • 19. Penetration into the anterior chamber via the conjunctival/scleral pathway.
    Schoenwald RD, Deshpande GS, Rethwisch DG, Barfknecht CF.
    J Ocul Pharmacol Ther; 1997 Feb; 13(1):41-59. PubMed ID: 9029439
    [Abstract] [Full Text] [Related]

  • 20. Lack of prostaglandin F2 alpha metabolism by human ocular tissues.
    Cheng-Bennett A, Poyer J, Weinkam RJ, Woodward DF.
    Invest Ophthalmol Vis Sci; 1990 Jul; 31(7):1389-93. PubMed ID: 2365570
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.